The Weekend Rip!
Presented by
The Weekend Rip
Happy Weekend!
Stocks pushed to records as AI leadership and easing rate fears kept investors risk-on despite war and oil-supply threats. SpaceX spending, AMD’s slowdown, and unforgiving earnings reactions tested that appetite before weak jobs data revived the bad-news-is-good-news trade. The Dow cleared 54,000, but the rally ended with an uncomfortable bargain: higher stocks built on softer labor and unresolved geopolitics.
Let’s recap and prep you for the week ahead. 📝
Monday 🤖: Semiconductor leadership kept investors risk-on and pushed the Dow through 53,000 despite the Middle East conflict. Palantir and Snap rewarded that appetite after hours with accelerating growth and stronger guidance. Crude’s sharp retreat offered relief, but threats to regional oil shipments kept the geopolitical warning light on.
Tuesday 🚀: Stocks returned to records as hopes for a Strait of Hormuz agreement cooled Treasury yields and kept investors leaning risk-on. AI remained the favorite trade until SpaceX’s spending spree and AMD’s slowing momentum turned strong results into after-hours selloffs. The rally survived the closing bell, but the bills landed just after it.
Wednesday 🥇: A defensive rotation kept the Dow afloat while tech and energy absorbed the damage. SpaceX’s massive AI bill turned Nvidia into the winner and AMD into collateral, while consumer earnings rewarded companies delivering profits now. Gold surged and SanDisk fell after hours, proving investors wanted protection and perfection at the same time.
Thursday 🛢️: The U.S.-Iran conflict and rising crude put the session on defense, with energy holding up while risk appetite faded. Earnings exposed the market’s perfection problem as storage, advertising, beverages, and public-safety tech all fell despite pockets of strong growth. MARA’s $611.3M loss and Trade Desk’s guidance shock kept the after-hours warning light flashing.
Friday 🥴: Stocks climbed after a surprise decline in July payrolls lowered expectations for another Fed rate increase. AI enthusiasm, a SpaceX rebound, and an energy-drink leadership revolt gave traders plenty to chase. The celebration came with an awkward catch: Wall Street’s good news was thousands of disappearing jobs.
🤩 This week’s Stocktwits Top 25 showed how momentum movers fared vs. the indexes.
Here are the closing prices:
SPONSORED BY ANNOVIS BIO
Annovis (ANVS) Hits Full Enrollment in Pivotal Phase 3 Alzheimer’s Trial
Annovis Bio announced full enrollment of its pivotal Phase 3 trial testing buntanetap in early Alzheimer’s disease, completing recruitment of 800 patients. Patients were selected using a pTau217 blood biomarker that confirms active Alzheimer’s pathology, a biomarker-driven design that is a key differentiator, ensuring the trial population reflects patients most likely to respond to treatment.
The trial will test both the symptomatic and disease-modifying effects of daily treatment with buntanetap, an orally administered pill with a distinct mechanism of action and a strong safety profile. This sets it apart from existing anti-amyloid antibody treatments.
Full enrollment marks a major derisking milestone, moving Annovis a step closer to topline data, expected in Q1 2027, followed by regulatory engagement for market approval. Investors should watch for readout timing as the next catalyst.
*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
THE BRIEF
Need a concise summary of what’s going on this week? Look no further. Here’s a rundown of this week’s earnings and economic data.
Earnings This Week
Above is a quick summary. Check out the full Stocktwits earnings calendar for the other names reporting this week.
Economic Calendar
In addition to the above, check out this week’s complete list of economic releases.
SPONSORED BY INVESTOR’S BUSINESS DAILY
Join us for IBD’s latest Virtual Trading Summit on Saturday, August 15th!
In this free two-hour online workshop, you’ll learn the fundamentals of sound stock market investing directly from IBD®, the trusted leader in investing education for over 40 years. You’ll walk away with time-tested strategies for outperforming the market and a list of actionable stocks that are setting up for big gains. IBD’s Jonathan Howard and Scott St. Clair will cover:
1. Proven strategies for picking winning stocks
2. How to avoid common investing mistakes
3. Recognizing signs of a market correction—and when to take action
4. Managing risk and maximizing profits with IBD’s time-tested investing system
Register today to join us for this live virtual workshop! Please note that this event will not be recorded for later viewing.
*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
ST EDITOR’S PICKS
Links That Don’t Suck 🌐
🆘 2 key checks on AI infrastructure and inflation: What to watch this week
⚠️ Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
🧓 From Freddie Mac to Zoetis: Burry’s Five Buys and Chip Short
👾 Myspace eyes comeback as an ‘antidote’ to social media fatigue — but it may be a long shot
Get In Touch 📬
Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.
Terms & Conditions 📝
Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋
